Re:NewCell AB (publ)
19.10.2021 14:17:20 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / October 19, 2021 / Re:NewCell AB (publ) (FRA:6QP) (STO:RENEW) Today, Renewcell and Kelheim Fibres Gmbh have signed a Letter of Intent for a long term commercial collaboration to add the crucial missing link for a circular economy for textiles in Europe. Together, the two technology leaders will collaborate on developing commercial scale production of superior quality viscose fibers from up to 10 000 tonnes of Renewcell's 100% textile recycled material Circulose® annually. The collaboration paves the way toward a fully European closed loop in which textile waste is collected, recycled and regenerated into new Circulose® fibers for people that want to reduce their fashion footprint significantly.
"European fashion consumption has great impact on climate and the environment globally. It also contributes to tremendous amounts of waste going into landfill and incinerators either in Europe or abroad after export. We will now work with Kelheim to prevent waste and reduce the need for virgin resources, while also enabling a fully regional supply of low impact circular fibers for textiles" comments Patrik Lundström, CEO of Renewcell. "We are thrilled for the opportunity to work closely with a partner like Kelheim, who is at the leading edge of innovation and sustainability in this industry" he adds.
Craig Barker, CEO at Kelheim Fibres adds: "We see an excellent fit between our two companies, not only on the technical side - with Renewcell we have found a highly professional partner who shares our vision for future-forward technologies that enable full circularity in the textile chain. Finding the answers to the challenges of our times is what drives us every day.
Our recycled cellulose fibre solution - made of Renewcell's Circulose® and manufactured using environmentally sound processes at our Kelheim plant - is an answer to the fashion industries need for sustainable, resource- and waste-reducing solutions, and a more regional and reliable supply chain."
About Renewcell
Founded by innovators from Stockholm's KTH Royal Institute of Technology in 2012, Re:NewCell AB (publ) (‘Renewcell') is a multi-award-winning sustaintech company based in Sweden. The company's vision is to inspire an Industrial Evolution to a sustainable world by producing high quality materials from recycled textiles.
Through its patented process, Renewcell is able to upcycle cellulosic textile waste, such as cotton clothes, transforming it into a pristine new material called Circulose®. Fast Company name Renewcell as one of the World's Most Innovative Companies 2021. Circulose® was also included on TIME Magazine's list of the 100 Best Inventions 2020.
Renewcell is a publicly listed company with shares traded on Nasdaq First North Premier Growth
Market with the ticker name RENEW and ISIN code SE0014960431. FNCA Sweden AB is Renewcell's Certified Adviser, +46(0)8-528 00 399, info@fnca.se .
CONTACT:
Presskontakt Renewcell
Harald Cavalli-Björkman
harald.cavalli-bjorkman@renewcell.com
+46 70 590 32 04
About Kelheim Fibres
Kelheim Fibres GmbH is the world's leading manufacturer of viscose speciality fibres.Innovative products, flexible technologies and an exceptional focus on sustainability form the foundation of the company's success.
Our plant-based speciality fibres are used in most diverse applications from fashion, hygiene and medical products to nonwovens and speciality papers. They offer an environmentally sound alternative to petroleum-based materials in a broad range of different end products - while maintaining or even enhancing the functional performance of the product. The production takes place exclusively in Germany and complies with the strict German environmental legislation. Our closed-loop philosophy and an energy-efficient way to operate our plants help to save valuable resources. Kelheim Fibres is the first viscose manufacturer worldwide with an EMAS-validated environmental management system. www.kelheim-fibres.com
PR Contact Kelheim Fibres
Stefanie Heigl
Tel: +49 9971 99 63 659
E-Mail: stefanie.heigl@kelheim-fibres.com
Image Attachments
Patrik Lundström, CEO Renewcell
Attachments
Renewcell and Kelheim Fibres form collaboration to establish a European closed loop for fashion
SOURCE: Re:NewCell AB (publ)
View source version on accesswire.com:
https://www.accesswire.com/668697/Renewcell-and-Kelheim-Fibres-Form-Collaboration-to-Establish-a-European-Closed-Loop-for-Fashion
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2025 Accomplishments and Outlook for 20265.2.2026 12:00:00 CET | Press release
Datavault AI signed $49M of Tokenization and Technology Licensing agreements in Q4'25 that impact FY2025 and FY2026 Revenue. Revenue: Datavault AI expects at least $30 million in revenue for FY2025, compared to $2.7 million in FY2024. This represents an increase of more than 1,000% growth in our revenue over 2024. The Company continues to expand to drive substantial near- and long-term accretion to our cash flows and earnings with a revenue target for 2026 of at least $200 million. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / February 5, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today issued a letter from Nathaniel Bradley, its Chief Executive Officer, to its stockholders highlighting the Company's accomplishments in 2025 and its outlook for 2026. A MESSAGE FROM OUR CHIEF EXECUTIVE OFFICER Dear Datavault AI Stockholders, I would like t
AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release
Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica
Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release
OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to
Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release
CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom